Drug intelligence / Profile preview

CTN-013

Development stage: Preclinical
Lead developer: Centenaire Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CTN-013 is a monoclonal antibody drug candidate that acts as an inhibitor of MUC16 (Mucin-16), a cell surface glycoprotein highly expressed in certain cancers. It was initially developed by Centenaire Biosciences and is being investigated primarily for the treatment of ovarian cancer. The drug is currently in preclinical development and targets neoplasms, endocrinology and metabolic diseases, as well as urogenital diseases through its action on MUC16[1].

Targets

MUC16 (Mucin-16)

Beyond the preview

Go deeper on CTN-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN-013.

Explore the full profile